Full Year 2023 Investor Presentation

43 Investor presentation Full year 2023 GLP-1 mechanism of action and potential therapeutic opportunities GLP-1 mechanism of action when blood sugar levels increase Creates sense of satiety in the brain Semaglutide holds a plethora of therapeutic opportunities¹ FOCUS - Diabetic retinopathy outcomes trial Semaglutide s.c; ~1,500 patients, T2D ≥10 years SOUL - Cardiovascular outcomes trial Diabetes Brain PAD Reduces glucagon secretion in the liver GLP-1 Liver Slows gastric emptying Stomach 1 List is not exhaustive Pancreas Increases insulin secretion in the pancreas CVD Oral semaglutide; ~9,600 patients, T2D, established CVD or CKD CKD FLOW - Chronic kidney disease outcomes trial Semaglutide 1.0 mg; ~3,200 patients, T2D, moderate to severe CKD STRIDE - Peripheral artery disease trial Semaglutide 1.0 mg; ~ 800 patients with T2D and PAD SELECT - Cardiovascular outcomes trial Obesity Semaglutide 2.4 mg, ~17,500 patients with obesity and without diabetes, event driven Heart Failure Brain disorders MASH STEP-HFPEF Semaglutide 2.4 mg; ~ 600 patients with obesity-related HFPEF Alzheimer's Disease - Oral Semaglutide 14 mg; ~ 3,700 patients with early Alzheimer's disease Semaglutide in MASH Semaglutide s.c.; phase 3 and 2 trials Sc: Subcutaneous; T2D: Type 2 diabetes; CVD: Cardiovascular disease; CKD: Chronic kidney disease; MASH: Metabolic dysfunction-associated steatohepatitis; PAD: Peripheral artery disease Novo NordiskⓇ

View entire presentation